Abstract
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are, with psoriatic arthritis, the most frequent rheumatic diseases. A better understanding of pathophysiology of these diseases had led to the development of new treatments refered as to biologic agents and, among them, TNF blocking agents have a major role. The knowledge of these drugs in terms of mechanisms of action, indications and potentials side effects has to be known to improve the efficacy/tolerance balance. Although these 3 anti-TNFalpha agents are currently used, new TNF blocking agents are under evaluation and should increase the number of drugs available within the next months.
MeSH terms
-
Adalimumab
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy*
-
Clinical Trials as Topic
-
Etanercept
-
Humans
-
Immunoglobulin G / therapeutic use
-
Infliximab
-
Receptors, Tumor Necrosis Factor / antagonists & inhibitors
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Spondylitis, Ankylosing / drug therapy*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Adalimumab
-
Etanercept